Thomas J. Anchordoquy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas J. Anchordoquy has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Jamie L. Betker
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States
10 shared publicationsMichael W. Graner
Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045
4 shared publicationsJamie L Betker
Skaggs School of Pharmacy & Pharmaceutical Sciences, University of Colorado, 12850 E. Montview Blvd, Aurora, CO 80045 USA
3 shared publicationsLong Xu
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E. Montview Blvd., Aurora, Colorado 80045, United States
3 shared publicationsTyson Smyth
University of Colorado Denver, Anschutz Medical Campus, Department of Pharmaceutical Sciences, Aurora, CO, USA
3 shared publicationsJamie Betker
University of Colorado School of Pharmacy, Aurora, Colorado 80045, USA
2 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by Wolters Kluwer Health in Menopause
Regeneration of the structure and function of estrogen-deficient vaginal epithelium by a novel phytoestrogen-related compound
Objective: The loss of estradiol production that accompanies natural aging or therapeutic intervention (oophorectomy or estrogen suppression) precipitates atrophic changes in the vaginal epithelium responsible for a plethora of symptoms that, collectively, are termed genitourinary syndrome of menopause. While systemic or local hormone replacement therapy can ameliorate these symptoms, their use faces resistance from women and their physicians concerned about the risks of estrogen therapy. The goal of this study is to evaluate an alternative approach to reversing vaginal atrophy that follows the loss of estradiol. Methods: This study employs the ovariectomized rat model of menopause. Ovariectomized rats exhibit atrophic changes in the vaginal epithelium, much like humans. We delivered a novel estrogenic flavone, 3-fluoro 6,4’-dihydroxyflavone (3F), by vaginal suppository. This compound was developed and chosen for modest potency as an estrogen and inactivation once in the circulation to minimize the potential for systemic activity. Results: Vaginal administration of this flavone regenerates the structure of atrophic vaginal epithelium. This is accompanied by restoration of mucin secretion and expression of anti-microbial proteins. Greater mucin expression is seen following 3F-treatment compared with estradiol. Vaginal regeneration is accomplished without stimulating cell proliferation in the vagina or endometrial epithelium. Conclusions: The combination of local delivery, modest potency, liver metabolism, and elimination creates safeguards that support the potential for human use of 3F to alleviate symptoms associated with estrogen-deficient vaginal atrophy without the risks of systemic hormone therapy or local steroidal estrogens.
- 7 July 2026
- Published by Wolters Kluwer Health in Menopause
Open AccessRegeneration of the structure and function of estrogen-deficient vaginal epithelium by a novel phytoestrogen-related compound
Objective: The loss of estradiol production that accompanies natural aging or therapeutic intervention (oophorectomy or estrogen suppression) precipitates atrophic changes in the vaginal epithelium responsible for a plethora of symptoms that, collectively, are termed genitourinary syndrome of menopause. While systemic or local hormone replacement therapy can ameliorate these symptoms, their use faces resistance from women and their physicians concerned about the risks of estrogen therapy. The goal of this study is to evaluate an alternative approach to reversing vaginal atrophy that follows the loss of estradiol. Methods: This study employs the ovariectomized rat model of menopause. Ovariectomized rats exhibit atrophic changes in the vaginal epithelium, much like humans. We delivered a novel estrogenic flavone, 3-fluoro 6,4’-dihydroxyflavone (3F), by vaginal suppository. This compound was developed and chosen for modest potency as an estrogen and inactivation once in the circulation to minimize the potential for systemic activity. Results: Vaginal administration of this flavone regenerates the structure of atrophic vaginal epithelium. This is accompanied by restoration of mucin secretion and expression of anti-microbial proteins. Greater mucin expression is seen following 3F-treatment compared with estradiol. Vaginal regeneration is accomplished without stimulating cell proliferation in the vagina or endometrial epithelium. Conclusions: The combination of local delivery, modest potency, liver metabolism, and elimination creates safeguards that support the potential for human use of 3F to alleviate symptoms associated with estrogen-deficient vaginal atrophy without the risks of systemic hormone therapy or local steroidal estrogens.
- 18 December 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (7) , 1926-1936
The Effect of Repeat Administration of Lipoplexes on Gene Delivery, Biodistribution, and Cytokine Response in Immunocompetent Tumor-Bearing Mice
- 18 December 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (7) , 1926-1936
The Effect of Repeat Administration of Lipoplexes on Gene Delivery, Biodistribution, and Cytokine Response in Immunocompetent Tumor-Bearing Mice
- Open Access
- 22 September 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (10) , 2893-2894
Escaping to silence using an endosome-disrupting polymer
- 22 September 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (10) , 2893-2894
Open AccessEscaping to silence using an endosome-disrupting polymer
- 1 April 2020
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 109 (4) , 1573-1580
The Use of Lactose as an Alternative Coating for Nanoparticles
- 1 April 2020
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 109 (4) , 1573-1580
The Use of Lactose as an Alternative Coating for Nanoparticles
- 1 April 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (4) , 1496-1505
The Potential of Exosomes From Cow Milk for Oral Delivery
- 1 April 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (4) , 1496-1505
The Potential of Exosomes From Cow Milk for Oral Delivery
- 1 January 2019
- Published by Future Science Ltd in Therapeutic Delivery
- Vol. 10 (1) , 11-20
A novel method for conjugating the terminal amine of peptide ligands to cholesterol: synthesis iRGD-cholesterol
Aim: Conventional conjugation reactions often involve the use of activated PEG as a linker, but concerns about PEG-mediated reduction in intracellular delivery and enhanced immunogenicity have generated interest in developing methods that eliminate the need for a PEG linker. Materials & methods: Reaction conditions were identified that specifically couples the terminal amine of a cyclic iRGD peptide (CRGDRGPDC) to the hydroxyl moiety of cholesterol through a short carbamate linker. Results & conclusion: Using this method for synthesizing iRGD-cholesterol, peptide ligands can be incorporated into lipid-based delivery systems, thereby eliminating concerns about adverse reactions to PEG. Toxicity and stability data indicate low toxicity and adequate serum stability at low ligand levels.
- 1 January 2019
- Published by Future Science Ltd in Therapeutic Delivery
- Vol. 10 (1) , 11-20
A novel method for conjugating the terminal amine of peptide ligands to cholesterol: synthesis iRGD-cholesterol
Aim: Conventional conjugation reactions often involve the use of activated PEG as a linker, but concerns about PEG-mediated reduction in intracellular delivery and enhanced immunogenicity have generated interest in developing methods that eliminate the need for a PEG linker. Materials & methods: Reaction conditions were identified that specifically couples the terminal amine of a cyclic iRGD peptide (CRGDRGPDC) to the hydroxyl moiety of cholesterol through a short carbamate linker. Results & conclusion: Using this method for synthesizing iRGD-cholesterol, peptide ligands can be incorporated into lipid-based delivery systems, thereby eliminating concerns about adverse reactions to PEG. Toxicity and stability data indicate low toxicity and adequate serum stability at low ligand levels.
- 1 September 2018
- Published by Elsevier in Journal of Controlled Release
- Vol. 286, 85-93
Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery
- 1 September 2018
- Published by Elsevier in Journal of Controlled Release
- Vol. 286, 85-93
Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery
- 14 July 2017
- Published by Elsevier in Journal of Controlled Release
- Vol. 262, 87-90
Watching the gorilla and questioning delivery dogma
- 14 July 2017
- Published by Elsevier in Journal of Controlled Release
- Vol. 262, 87-90
Watching the gorilla and questioning delivery dogma
- 1 March 2017
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 106 (3) , 872-881
Nonadditive Effects of Repetitive Administration of Lipoplexes in Immunocompetent Mice
- 1 March 2017
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 106 (3) , 872-881
Nonadditive Effects of Repetitive Administration of Lipoplexes in Immunocompetent Mice
- 1 January 2017
- Published by American Chemical Society (ACS)
- p. 71-93
Utilizing Cholesterol Nanodomains for Nucleic Acid Delivery
- 1 January 2017
- Published by American Chemical Society (ACS)
- p. 71-93
Utilizing Cholesterol Nanodomains for Nucleic Acid Delivery